{‘She lacks little expertise’: this US healthcare community girds for Høeg's role at the FDA.

While the US proceeds with unprecedented adjustments to its vaccination recommendations, a particular individual has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid vaccinations throughout the pandemic and has focused upon possible deaths following Covid vaccination in her brief position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders planned to unveil radical changes to the pediatric immunization program earlier this month, aligning the US with the Danish vaccine program, according to reports – a major change that would place the US out of step with a large portion of the global community with no evidence for improved outcomes. This reveal has been postponed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to speak at the event. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth person to head the office this calendar year.

A Shift at the Agency

This interim role may indicate a closer partnership between the drug and vaccine divisions as Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US so as to align more like Denmark, a nation with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

To date comments, she has kept her attention on vaccines – usually the responsibility of Dr. Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Qualifications

Høeg has little discernible experience in pharmaceutical research, oversight or leadership, which has been customary for past leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous directors of CBER would “understand regulatory frameworks and the science of drug development”, commented Janet Woodcock. “Objectively, she lacks the type of experience that prior appointees who led CBER have had.”

CDER has an immense portfolio at the FDA, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the generic drug division approves a multitude of generic medications. There is also a biosimilars program, over-the-counter program and so forth, and every single one must be supervised,” Dr. Woodcock explained. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a significant leadership element to the role, which oversees over 5,000 personnel. “It’s a huge administrative position, if you perform it correctly,” Woodcock said.

Response and Controversial Policies

In response to questions about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among FDA leaders on immunizations, a spokesperson responded that the “questions stem from flawed premises”.

“Her experience aligns with the responsibilities of her role,” the spokesperson explained, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's controversial expedited review system, a controversial rapid medication authorization process that allegedly troubled her predecessors. “By what process are these drugs being picked for this voucher program? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent regulations of pharmaceuticals, aside from shots.”

Public History on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, track record, Howard observe. She authored a research paper using unconfirmed public submissions to determine the rate of heart inflammation following Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the new administration included altering regulations for new vaccines and ending “optional” vaccines, she remarked after the election on a online show. At the FDA, Dr. Høeg has allegedly proposed barring young men from getting Covid vaccinations.

“She’s an thorough ideologue who begins with her conclusions and tailors the evidence to retrofit the evidence in a very misleading, dishonest manner,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg became part of fellow skeptics, {like|